Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.

Tivicay (dolutegravir) - ViiV Healthcare

Rukobia (fostemsavir extended release) - ViiV Healthcare

http://www.ncbi.nlm.nih.gov/pubmed/42703616

Andrew Clark; Antonella Castagna; Bo Li; Bryn Jones; Cynthia Donovan; Fangfang Du; Iacopo Marcon; Manyu Prakash; Marcia Wang

Sep 8, 2026